RxDoctor Payments Data

Sedo Tamakloe, MD

Internal Medicine · Ruston, LANPI 1386652006

Payments from drug & device makers

$182in general payments, 2019–2025

Across 11 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$29
  • AbbVie$24
  • Lilly USA, LLC$23
  • Novartis$22
  • GSK$20
  • AstraZeneca$18
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$182100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$182 in reported general payments places this provider in the 35th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$127,933
Medicare patients
380
Services billed
1,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate40$157,198
AustedoDeutetrabenazine24$97,889
EliquisApixaban257$96,995
Austedo XrDeutetrabenazine20$82,437
RexultiBrexpiprazole65$53,371
CresembaIsavuconazonium Sulfate12$47,742
JardianceEmpagliflozin72$26,761
EntrestoSacubitril/Valsartan63$24,897
VelphoroSucroferric Oxyhydroxide22$22,344
JanuviaSitagliptin Phosphate68$19,481
BrilintaTicagrelor60$15,159
TivicayDolutegravir Sodium12$12,681
MyrbetriqMirabegron43$11,932
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,888
FarxigaDapagliflozin Propanediol24$9,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$15$26,76172 claims
AstraZenecaBrilinta, Farxiga$18$25,01784 claims
NovartisEntresto$22$24,89763 claims
GSKTrelegy Ellipta, Breo Ellipta$20$19,01737 claims
Johnson & JohnsonXarelto$16$9,08826 claims
Lilly USA, LLCHumalog$23$2,21926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Ruston

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →